Laboratoire Francais du Fractionnement et des Biotechnologies
发明人:
Dominique Bourel,Sylvie Jorieux,Christophe De Romeuf,Philippe Klein,Christine Gaucher,Nicolas Bihoreau,Emmanuel Nony
申请号：
US13930070
公开号：
US09109020B2
申请日:
2013.06.28
申请国别(地区):
US
年份:
2015
代理人:
摘要：
The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.
